keyword
https://read.qxmd.com/read/38094140/intravenous-methadone-in-the-management-of-acute-postoperative-pain-in-a-chronic-cancer-pain-patient-a-case-report-and-review-of-the-literature
#1
Khang Duy Ricky Le, Jean Hua
KEY CLINICAL MESSAGE: The current landscape of literature highlights that there is insufficient well-powered and robust evidence to support the integration of intravenous methadone into current guidelines and frameworks in supporting the pain management of cancer patient with complex pain syndromes. However, there is preliminary evidence, both from the literature as well as this case study that highlights intravenous methadone may be efficaciously and safety used for the management of postoperative pain in cancer patients with chronic pain undergoing operative management...
December 2023: Clinical Case Reports
https://read.qxmd.com/read/37790027/iatrogenic-side-effects-of-pain-therapies
#2
REVIEW
Christopher Gharibo, Asbjørn M Drewes, Frank Breve, Martina Rekatsina, Marco Antonio Narvaez Tamayo, Giustino Varrassi, Antonella Paladini
Pain regimens, particularly for chronic cancer and noncancer pain, must balance the important analgesic benefits against potential risks. Many effective and frequently used pain control regimens are associated with iatrogenic adverse events. Interventional procedures can be associated with nerve injuries, vascular injuries, trauma to the spinal cord, and epidural abscesses. Although rare, these adverse events are potentially catastrophic. Pharmacologic remedies for pain must also consider potential side effects that can occur even at therapeutic doses of over-the-counter remedies such as paracetamol (acetaminophen) or nonsteroidal anti-inflammatory drugs...
September 2023: Curēus
https://read.qxmd.com/read/37757956/comparison-of-the-effects-of-oprm1-a118g-polymorphism-using-different-opioids-a-prospective-study
#3
COMPARATIVE STUDY
Miho Takemura, Kazuyuki Niki, Yoshiaki Okamoto, Tomohiro Kawamura, Makie Kohno, Yoshinobu Matsuda, Kenji Ikeda
CONTEXT: μ-opioid receptor gene (OPRM1) A118G polymorphism (rs1799971) causes loss of N-glycosylation sites at the extracellular domain of μ-opioid receptors. G-allele carriers show a limited response to morphine; however, studies investigating the impact of A118G polymorphism on the efficacy of opioids other than morphine are limited. OBJECTIVE: To compare the impact of A118G polymorphism on the efficacy of various opioids. METHODS: This prospective cohort study enrolled 222 in-patients administered one of the following opioid therapies for cancer pain as part of an opioid introduction or rotation strategy: tapentadol extended-release tablets, methadone tablets, hydromorphone controlled-release tablets, oxycodone controlled-release tablets, or transdermal fentanyl patches...
January 2024: Journal of Pain and Symptom Management
https://read.qxmd.com/read/37588788/nociceptin-orphanin-fq-receptor-expression-in-primary-human-umbilical-vein-endothelial-cells-is-not-regulated-by-exposure-to-breast-cancer-cell-media-or-angiogenic-stimuli
#4
JOURNAL ARTICLE
Despina Giakomidi, Sonja Khemiri, Wadhah Mahbuba, David G McVey, Fatin Al-Janabi, Remo Guerrini, Girolamo Calo, Shu Ye, David G Lambert
BACKGROUND: Opioid receptors are naloxone-sensitive (MOP [mu: μ], DOP [delta: δ], and KOP [kappa: κ]) and naloxone-insensitive Nociceptin/Orphanin FQ (N/OFQ) peptide receptor (NOP). Clinically, most opioid analgesics target MOP. Angiogenesis is the formation of new blood vessels and involves endothelial cell activation, proliferation, and migration. The effect of opioids on this process is controversial with no data for NOP receptor ligands. METHODS: We used patient-derived human umbilical vein endothelial cells (HUVECs) treated with media from the Michigan Cancer Foundation-7 (MCF-7) breast cancer cells or vascular endothelial growth factor (VEGF; 10 ng ml-1 ) and fibroblast growth factor (FGF; 10 ng ml-1 ) as angiogenic stimuli...
December 2022: BJA Open
https://read.qxmd.com/read/37533563/methylnaltrexone-treatment-for-opioid-induced-constipation-in-patients-with-and-without-cancer-effect-of-initial-dose
#5
Bruce H Chamberlain, Michelle Rhiner, Neal E Slatkin, Nancy Stambler, Robert J Israel
PURPOSE: Opioid-induced constipation (OIC) is a common side effect of opioid therapy. Methylnaltrexone (MNTX) is a selective, peripherally acting μ-opioid receptor antagonist, with demonstrated efficacy in treating OIC. We pooled results from MNTX clinical trials to compare responses to an initial dose in patients with chronic cancer and noncancer pain. PATIENTS AND METHODS: This post hoc analysis used pooled data from 3 randomized, placebo-controlled studies of MNTX in patients with advanced illness with OIC...
2023: Journal of Pain Research
https://read.qxmd.com/read/37498667/multimodal-pain-control-utilizing-buprenorphine-for-robotic-assisted-laparoscopic-prostatectomy-a-quality-improvement-comparison-to-conventional-opioid-management
#6
JOURNAL ARTICLE
Mohammad Hajiha, Donna Lien, Jo Ann Johnson, Ivan Muchiutti, Jasmine Sran, Alexandra Vacaru, Akin S Amasyali, Leonard Soloniuk, Kanha Shete, Sonia Wraich, Brian Hu, Duane D Baldwin, Ruth Belay, Jonathan Malonado, Mohamed Keheila, Ashley Li, Gary Stier, Justin Calvert, Melody Chang, Michael Douglas, Aviram Assidon, Herbert Ruckle
PURPOSE: This study investigated the effectiveness of buprenorphine as an alternative to the use of conventional opioids perioperatively in an effort to help mitigate the impact of the use of perioperative conventional opioids for patients undergoing robotic assisted laparoscopic prostatectomy. MATERIALS AND METHODS: Outcomes of patients with localized prostate cancer undergoing robotic assisted laparoscopic prostatectomy were examined before and after implementation of novel quality improvement study that included receiving buprenorphine compared to conventional opioids for pain control intraoperatively and postoperatively...
July 27, 2023: Urology Practice
https://read.qxmd.com/read/37453566/mu-and-kappa-opioid-receptor-immunolabeling-indicates-the-prognosis-of-oropharyngeal-squamous-cell-carcinoma-a-cross-sectional-observational-study
#7
JOURNAL ARTICLE
Thinali Sousa Dantas, Paulo Goberlânio de Barros Silva, Osias Vieira de Oliveira Filho, Iana Aragão Magalhães, Ana Paula Negreiros Nunes Alves, Maria do Perpétuo Socorro Saldanha Cunha, Mário Rogério Lima Mota, Renata Ferreira de Carvalho Leitão, Fabrício Bitu Sousa
BACKGROUND: Opioids are the most effective drugs currently available for cancer pain management. The administration of morphine, in addition to its analgesic effect, can alter tumor development. OBJECTIVE: To characterize the immunoexpression of opioid receptors µ and κ in oropharyngeal squamous cell carcinoma, and correlate it with prognostic factors, proliferation markers, and cell death. MATERIALS AND METHODS: A retrospective, cross-sectional observational study was carried out with 50 patients diagnosed at Haroldo Juaçaba Hospital...
July 13, 2023: Journal of Stomatology, Oral and Maxillofacial Surgery
https://read.qxmd.com/read/37226458/co-administration-of-nalbuphine-to-improve-morphine-tolerance-in-mice-with-bone-cancer-pain
#8
JOURNAL ARTICLE
Bingxu Ren, Jiannan Zhang, Xiaohu Yang, Dapeng Sun, Duanyang Sheng, Qiang Fang, Zhonghua Ji
BACKGROUND: Kappa-opioid receptor (KOR) agonists are known for having opposite and/or different effects compared with Mu-opioid receptor (MOR) agonists. This study is aimed at clarifying the analgesic effect and tolerance of nalbuphine combined with morphine, and quantifying the mRNA and protein expression of spinal MOR and KOR in a mouse bone cancer pain (BCP) model treated with nalbuphine and morphine. METHOD: BCP model was prepared in C3H/HeNCrlVr Mice by implanting the sarcoma cells into the intramedullary space of the femur...
2023: Molecular Pain
https://read.qxmd.com/read/37064155/mu-opioid-receptor-mrna-overexpression-predicts-poor-prognosis-among-18-common-solid-cancers-a-pan-cancer-analysis
#9
JOURNAL ARTICLE
Wei Sun, Shaohui Zhuang, Minghua Cheng, Zeting Qiu
BACKGROUND: Opioids are widely used for patients with solid tumors during surgery and for cancer pain relief. We conducted a pan-cancer genomic analysis to investigate the prognostic features of Mu opioid receptor ( MOR ) mRNA expression across 18 primary solid cancers. METHODS: All the data of cancer with MOR mRNA were retrieved from cBioPortal for Cancer Genomics. Logistic regression was used to determine the associations between MOR mRNA expression and clinicopathological features...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37003560/fentanyl-inhibits-cell-invasion-and-migration-by-modulating-nf-%C3%AE%C2%BAb-activation-in-glioma
#10
JOURNAL ARTICLE
Duan-Zheng Liu, Shi-Yuan Xu
Fentanyl is widely used for anesthesia and analgesia in cancer patients. Recent studies have revealed its anti-growth effect in several categories of cancer. Gliomas are the most common primary tumors in the central nervous system with poor prognosis. To investigate the effects of fentanyl on gliomas, glioma cells were treated with different concentrations of fentanyl both in vitro and in vivo. Consequences of proliferation and invasive phenotypes, and related protein expression were evaluated in two human glioma cell lines (U251 and U87)...
June 15, 2023: Brain Research
https://read.qxmd.com/read/36984494/a-retrospective-study-of-the-efficacy-and-safety-of-naldemedine-for-treatment-of-opioid-induced-constipation-in-patients-with-hepatobiliary-pancreatic-cancer
#11
JOURNAL ARTICLE
Teruhiko Kamiya, Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Shiro Koizuka, Taeko Saito, Kyoko Obayashi, Kyoichi Kaira, Koichi Minato
Background and Objectives : Opioid analgesics, which are used for cancer-related pain management, cause opioid-induced constipation (OIC). Naldemedine, a peripheral opioid receptor antagonist, is an OIC-modifying agent, but no focused efficacy and safety analysis has been conducted for its use in hepatobiliary pancreatic cancers. We performed a multi-institutional study on the efficacy and safety of naldemedine in patients with hepatobiliary pancreatic cancer using opioids in clinical practice. Materials and Methods : We retrospectively evaluated patients with hepatobiliary pancreatic cancer (including liver, biliary tract, and pancreatic cancers) treated with opioids and naldemedine during hospitalization at ten institutions in Japan from June 2017 to August 2019...
March 2, 2023: Medicina
https://read.qxmd.com/read/36971576/efficacy-and-safety-of-naldemedine-administration-for-opioid-induced-constipation-in-cancer-patients-with-poor-performance-status
#12
MULTICENTER STUDY
Yukiyoshi Fujita, Hisao Imai, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Shiro Koizuka, Taeko Saito, Kyoko Obayashi, Kyoichi Kaira, Koichi Minato
Background: Constipation is a concern among patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 and 4. Objectives: To assess naldemedine's efficacy and safety in cancer patients on opioids with poor PS. Design: Multicenter, retrospective study. Setting/Subjects: Japanese cancer patients with ECOG performance status 3 or 4 who received naldemedine. Measurements: Frequency of defecations before/after naldemedine use. Responders were patients whose defecation frequency increased to ≥3 times/week, from baseline ≥1 defecations/week over seven days after naldemedine administration...
April 2023: Journal of Palliative Medicine
https://read.qxmd.com/read/36565253/response-rates-to-methylnaltrexone-in-hospitalized-cancer-patients
#13
JOURNAL ARTICLE
David Harris, David Kalir, Cory Chevalier, Krista Dobbie, Flannery Fielding, Ruth Lagman, Ahed Makhoul, Susan McInnes, Sina Najafi, Kyle Neale, Lisa Rybicki, Melanie Robbins-Ong, Kathleen Neuendorf
Context: Methylnaltrexone is a peripherally-acting mu-opioid receptor antagonist studied in both cancer and non-cancer patients with opioid-induced constipation (OIC), but mostly in the outpatient setting. For adult hospitalized cancer patients with OIC, its effectiveness is unknown. Objectives: Describe the efficacy of methylnaltrexone for OIC in the inpatient setting, defined as bowel movement (BM) within 24 hours of methylnaltrexone administration. Methods: We performed a single-center, retrospective chart review of all hospitalized, adult patients with a cancer diagnosis who received methylnaltrexone from the palliative care team between January 1st, 2012 and July 1st, 2019...
December 24, 2022: American Journal of Hospice & Palliative Care
https://read.qxmd.com/read/36548911/an-update-on-the-use-of-pharmacotherapy-for-opioid-induced-bowel-dysfunction
#14
JOURNAL ARTICLE
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi
INTRODUCTION: With the growing rate of aging and the incidence of cancer and chronic diseases, there has been an upsurge in opioid prescription and abuse worldwide. This has been associated with increased reports of opioid-related adverse events, particularly opioid-induced bowel dysfunction (OIBD), calling for a rational clinical management strategy. AREAS COVERED: Through searching PubMed, Scopus, Cochrane Library, and Web of Science, exciting English literature was gathered as of January 1, 2017...
December 22, 2022: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/36441436/an-open-label-phase-ii-study-of-safety-and-clinical-activity-of-naltrexone-for-treatment-of-hormone-refractory-metastatic-breast-cancer
#15
JOURNAL ARTICLE
Jayanthi Vijayakumar, Tufia Haddad, Kalpna Gupta, Janet Sauers, Douglas Yee
The opioid receptor (OR) antagonist naltrexone inhibits estrogen receptor-α (ER) function in model systems. The goal of this study was to determine the clinical activity of naltrexone in patients with ER-positive metastatic breast cancer. Patients with hormone receptor positive metastatic breast cancer were enrolled on a phase II study of naltrexone. An escalating dose scheme was used to reach the planned dose of 50 mg daily. The primary objective of the study was to evaluate response to therapy as measured by stabilization or reduction of the tumor Maximum Standardized Uptake Value (SUVmax) at 4 weeks by PET-CT scan...
February 2023: Investigational New Drugs
https://read.qxmd.com/read/36430602/the-impact-of-p-glycoprotein-on-opioid-analgesics-what-s-the-real-meaning-in-pain-management-and-palliative-care
#16
REVIEW
Flaminia Coluzzi, Maria Sole Scerpa, Monica Rocco, Diego Fornasari
Opioids are widely used in cancer and non-cancer pain management. However, many transporters at the blood-brain barrier (BBB), such as P-glycoprotein (P-gp, ABCB1/MDR1), may impair their delivery to the brain, thus leading to opioid tolerance. Nonetheless, opioids may regulate P-gp expression, thus altering the transport of other compounds, namely chemotherapeutic agents, resulting in pharmacoresistance. Other kinds of painkillers (e.g., acetaminophen, dexamethasone) and adjuvant drugs used for neuropathic pain may act as P-gp substrates and modulate its expression, thus making pain management challenging...
November 16, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/35983971/mor-promotes-epithelial-mesenchymal-transition-and-proliferation-via-pi3k-akt-signaling-pathway-in-human-colorectal-cancer
#17
JOURNAL ARTICLE
Lingling Gao, Li Yang, Yiping He, Yi Liu, Pinbo Xu, Jun Zhang, Sailin Dai, Xing Luo, Zhirong Sun
The mu-opioid receptor (MOR), a membrane-bound G protein-coupled receptor, is implicated in progression and long-term outcome of several types of tumors. However, the expression and clinical significance of MOR in colorectal cancer (CRC) remain unclear. In this study, a total of 180 paraffin-embedded samples of paired tumors and normal tissues from CRC patients are used to explore expression levels of MOR by immunohistochemistry (IHC). Results show that MOR is highly expressed in tumors compared with that in paired normal tissues (P<0...
August 25, 2022: Acta Biochimica et Biophysica Sinica
https://read.qxmd.com/read/35875149/association-of-mu-opioid-receptor-expression-with-long-term-survival-and-perineural-nerve-invasion-in-patients-undergoing-surgery-for-ovarian-cancer
#18
JOURNAL ARTICLE
Hao Zhang, Mengdi Qu, Caihong Sun, Yanghanzhao Wang, Ting Li, Wei Xu, Zhirong Sun, Xiaoguang Zhang, Kefang Guo, Wankun Chen, Minli Sun, Changhong Miao
Background: Opioids are widely used during primary debulking surgery (PDS) for ovarian cancers, and a high mu-opioid receptor (MOR) expression predicts worse cancer outcomes. However, the impact of MOR expression on survival outcomes in ovarian cancers is still not clear. Methods: A retrospective cohort study was conducted in patients who underwent PDS in ovarian cancer patients. MOR expression was measured in tumor and normal tissue. Primary outcomes were overall survival (OS) and disease-free survival (DFS)...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35855248/multimechanistic-single-entity-combinations-for-chronic-pain-control-a-narrative-review
#19
REVIEW
Joseph Pergolizzi, Peter Magnusson, Flaminia Coluzzi, Frank Breve, Jo Ann K LeQuang, Giustino Varrassi
Atypical opioids such as tramadol, tapentadol, and cebranopadol combine two complementary mechanisms of action into a single molecule, creating novel analgesic agents. These are synthetic small molecules: cebranopadol is not yet market released; tramadol and tapentadol are commercially available and have immediate-release (IR) and extended-release (ER) formulations. Tramadol has been widely used in the United States in recent years and works as a prodrug in that its metabolites are active in inhibiting serotonin and norepinephrine reuptake...
June 2022: Curēus
https://read.qxmd.com/read/35795569/the-kappa-opioid-receptor-a-promising-therapeutic-target-for-multiple-pathologies
#20
REVIEW
Martin L Dalefield, Brittany Scouller, Rabia Bibi, Bronwyn M Kivell
Kappa-opioid receptors (KOR) are widely expressed throughout the central nervous system, where they modulate a range of physiological processes depending on their location, including stress, mood, reward, pain, inflammation, and remyelination. However, clinical use of KOR agonists is limited by adverse effects such as dysphoria, aversion, and sedation. Within the drug-development field KOR agonists have been extensively investigated for the treatment of many centrally mediated nociceptive disorders including pruritis and pain...
2022: Frontiers in Pharmacology
keyword
keyword
112554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.